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BRIEF REPORT

Association of SLCO1B1 *14 Allele with Poor Response to
Methotrexate in Juvenile Idiopathic Arthritis Patients
Laura B. Ramsey,1,2 Halima Moncrieffe,1,3 Chelsey N. Smith,4 Marc Sudman,3 Miranda C. Marion,5
Carl D. Langefeld,5 Mara L. Becker,4 and Susan D. Thompson1,3
Objective. Variants in the SLCO1B1 gene, encoding a hepatic methotrexate (MTX) transporter, affect clearance of
high-dose MTX. We tested whether in the *14 and *15 alleles of SLCO1B1 influenced the response to low-dose MTX
in juvenile idiopathic arthritis (JIA) patients.
Methods. The study included 310 JIA patients genotyped for three single nucleotide polymorphisms (SNPs) in
SLCO1B1 (rs4149056, rs2306283, and rs11045819). A patient’s SLCO1B1 diplotype was determined by combining
the SNPs into the *1a, *1b, *4, *5, *14, and *15 alleles. Number of active joints at follow-up (visit closest to 6 months
of treatment and prior to starting a tumor necrosis factor inhibitor) was used as the dependent variable in a negative
binomial regression model that included active joint count at baseline as a covariate.
Results. The SLCO1B1*14 allele was associated with less response to MTX (P = 0.024) and the *15 allele was not
associated with response to MTX (P = 0.392).
Conclusion. SLCO1B1 alleles may be associated with poor response to MTX in JIA patients. The *14 allele
has been associated with fast clearance (low exposure) after high-dose MTX in patients with leukemia. Thus, the
SLCO1B1 gene may be informative for precision dosing of MTX in JIA patients. Patients carrying the *14 allele may
require a higher dose than noncarriers to achieve a similar response to MTX.
INTRODUCTION
Juvenile idiopathic arthritis (JIA), the most common pediatric
rheumatic condition, manifests as a chronic inflammatory arthritis
that can result in morbidity and disability when inadequately treated
(1). For children with multiple affected joints, initial treatment often
consists of nonsteroidal anti-inflammatory drugs in conjunction
with methotrexate (MTX), a slow-acting disease-modifying antirheumatic drug (DMARD) (2). As a result of the newly recognized
early “window of opportunity” for treatment (3), rapid and effective disease control is an aim of clinicians and an expectation of
patients. However, MTX can take several months before the full
effect is realized, and even though about 30% of these children
will achieve a good response within the first 3 months and 60%-
70% by 6 months on MTX, waiting this time without a guarantee of
response is suboptimal when long-term outcomes are at stake (3).
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Variants in the SLCO1B1 gene, encoding a hepatic MTX
transporter, were the top findings in a genome-wide association
study focused on MTX clearance in pediatric leukemia patients
treated with high-dose MTX (4, 5). As is conventional with pharmacogenes, star nomenclature is used for SLCO1B1 to indicate
the alleles, which are categorized by the Clinical Pharmacogenetics Implementation Consortium by function (6). There are three no-
function alleles: *5, *15, and *17, and one increased function allele,
*14. Normal function alleles are *1a and *1b. Given the influence of
SLCO1B1 on the pharmacokinetics of high-dose MTX, we tested
the influence of this gene on the response to MTX in JIA patients.

PATIENTS AND METHODS
Three hundred thirty-four JIA patients of all subtypes, except
systemic JIA, treated with DMARD monotherapy were included in
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Table 1. Summary of patient cohort
JIA Subtype

N

Oligoarticular extended

45

Oligoarticular persistent

18

Polyarticular (RF-)

191

Polyarticular (RF+)

46

Psoriatic

7

Undifferentiated

3

Total

310

Self-reported race

N

African American

13

Asian

4

Caucasian

293

Self-reported gender
Female

N
245

Male

65

Age (years)

Mean (range)

Follow-up time (months)

Mean (range)

Dose at MTX start (mg/m2)

Mean (range)

7.3 (0.3-16.9)
5.6 (1.3-14)
11.6 (5-26.9)
Active joints at start

Mean (range)

Active joints at follow-up

Mean (range)

12.5 (2- 61)
6.8 (0-41)
MTX route

N

Subcutaneous

79

Oral

125

Unknown
SLCO1B1 alleles

106
a

Frequency

*1a (A-C-T )

53.0%

*1b (G-C-T )

14.8%

*14 (G-A-T )

15.7%

*15 (G-C-C )

15.3%

*5 (A-C-C )

1.1%

Abbreviation: JIA, juvenile idiopathic arthritis; N, number; RF, rheumatoid factor; MTX, methotrexate.
a
The SLCO1B1 alleles are defined by PharmGKB.org at SNPs
rs2306283 (A>G), rs11045819 (C>A), and rs4149056 (T>C).

this study. Patients enrolled in the local clinics (Cincinnati Children’s
Hospital Medical Center or Children’s Mercy Hospital) or in multicenter gene expression studies comprised the cohort (Table 1)
(7). Patients were enrolled in their respective studies from the start
of MTX treatment. Written, informed parental consent, and child
assent as appropriate, was obtained for each subject. This study
complies with the Helsinki Declaration and was approved by the
Institutional Review Boards of Cincinnati Children’s Hospital Medical Center and Children’s Mercy Hospital.

59

All patients met the International League of Associations
for Rheumatology (ILAR) or American College of Rheumatology
classification criteria for JIA or juvenile rheumatoid arthritis (JRA).
Patients recruited before ILAR criteria were published were originally classified using JRA criteria and subsequently reclassified for
this study by ILAR criteria. A patient was considered rheumatoid
factor (RF) negative on the basis of a single test. Information about
the presence or absence of RF was available for all patients. Of
the 334 patients eligible for inclusion in the study, exclusions were
made if they had less than two active joints (n = 3) at the baseline visit, (n = 3) had Down Syndrome (n = 3), had less than 1
month to MTX follow-up (n = 1), failed genotyping (n = 7), or were
given a dose of MTX <5 mg/m2 (n = 10). After these exclusions,
310 patients remained in the current analysis. No patients with
enthesitis-related arthritis were included in the study cohort, but
patients were not excluded based on this subtype of JIA. Data on
the route of administration of MTX was available for 204 patients
(Table 1). Genotyping of three single nucleotide polymorphisms
(SNPs) in SLCO1B1 (rs4149056, rs2306283, and rs11045819)
was performed with TaqMan probes (n = 275) or was available
from genome-wide arrays (n = 248) (8), with complete concordance in genotypes obtained on both platforms. When TaqMan
genotyping failed for rs2306283 (n = 20) and rs11045819 (n =
16), the genotype was imputed from a proxy SNP genotyped with
a genome-wide array (rs7973095 and rs11045821, respectively).
These proxy SNPs were chosen for the linkage disequilibrium
with r2 = 0.97 for rs2306283 and rs7973095 and r2 = 0.99 for
rs11045819 and rs11045821 in the EUR dataset of the 1000
genomes Phase 1 population (https://pubs.broadinstitute.org/
mammals/haploreg/haploreg.php) because 33 of the 36 missing
genotypes from TaqMan genotyping were in Caucasian patients.
The observed genotype frequencies were consistent with Hardy-
Weinberg equilibrium. A patient’s SLCO1B1 alleles were determined by these three SNPs that make up the *1a (wild-type), *1b
(rs2306283), *4 (rs11045819), *5 (rs4149056), *14 (rs2306283 +
rs11045819), and *15 (rs2306283 + rs4149056) alleles. The variant that distinguishes the *17 allele from the *15 allele was not genotyped (rs4149015). The Dandelion program within the SNPLASH
suite was used to implement the Expectation-Maximization algorithm to calculate haplotype frequency maximum likelihood estimates (https://github.com/guyrt/WFUBMC/). Given an individual’s
genotype at each SNP, all possible haplotype pairs were exported,
along with their probabilities. Each possible haplogenotype for an
individual is included in the analysis, weighted by the within-person
haplogenotype probability. The patients identified as carrying the
*15 allele could have either the *15 or the *17 allele because the
rs4149015 genotype was not obtained. Frequency of the alleles
in our cohort were similar to the expected population frequency
(9) and previous multiethnic cohort studies (4). The *4 allele was
not present in the patient samples, and the *5 allele was too rare
to test for association with MTX response (Table 1). The *1b allele
is considered to confer normal function and was not tested. To
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test for an association between *14 and *15 allele dosage (additive model) with active joint count (at the visit closest to 6 months
of treatment and prior to starting tumor necrosis factor inhibitor),
a negative binomial regression model was computed to where
the outcome is the active joint count at follow-up and the active
joint count at baseline was a covariate. The active joint count at
follow-up was chosen for the outcome variable with adjustment in
the regression model for baseline active joint count because the
magnitude of change depends on the number of joints affected
at baseline (for example, a reduction in two joints is different in
patients who start with three joints affected versus those who start
with 20 joints affected). The sample size was not large enough to
control for each subtype of JIA and, importantly, there has been
recent recognition in the limitation of the JIA ILAR classification
system, which is based primarily on clinical phenotype. Future
revisions in the JIA classification terminology based on pathophysiological and genetic features are likely (10, 11). The negative
binomial regression is a generalized linear model that is designed
for count data with overdispersion. Because two tests were computed (*14 and *15 alleles), P values of <0.025 were considered
statistically significant.
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Table 2. Parameters included in the analysis of active joint count at
follow-up using a maximum likelihood model
Estimate

SE

P Value

Baseline AJC

0.065

0.007

<0.0001

Age

−0.018

0.015

0.22

−0.0007

0.041

0.87

Gender

−0.180

0.160

0.26

SLCO1B1*14

0.267

0.131

0.04

Parameter

Follow-up time

Abbreviation: AJC, active joint count.

The median improvement during MTX monotherapy was 62.5%
for patients carrying no *14 alleles versus 50% for those carrying
one *14 allele, and for those carrying two *14 alleles, improvement
was 42.9%. There was no association between response to MTX
and the *15 allele (P = 0.392). When the model included additional
covariates that may be related to response (age, gender, and follow-up time; Table 2), the association with the SLCO1B1*14 allele
remained. When only Caucasian patients (n = 293) were included
in the model, the direction and magnitude of the effect of the
SLCO1B1*14 allele were similar (P = 0.043).

RESULTS

DISCUSSION

The SLCO1B1*14 allele was associated with less response
to MTX (less reduction of active joint count, P = 0.024, Figure 1).

The SLCO1B1*14 allele may be associated with poor
response to weekly low-dose MTX for JIA patients. This association remained significant after including other parameters in the
model that may be related to response (age, gender, follow-up
time) and restriction to Caucasian patients. In patients with leukemia receiving much higher doses of MTX (2-5 g/m2), the *14
allele has been associated with fast clearance and low exposure
(4). The *14 allele increases expression of the transporter (12),
which would likely result in more effective drug transport into the
liver to be excreted, thus lower blood concentrations, less MTX
in the target tissues, and less efficacy. The G allele of rs2306283
was associated with poor response to MTX in Slovenian rheumatoid arthritis patients (13), and this allele is included in the *1b,
*14, and *15 haplotypes. The *1b allele was not tested for association with MTX response in our study because it is defined by
the Clinical Pharmacogenetics Implementation Consortium as
conferring normal activity of the transporter (6). The *15 allele was
tested for association with MTX response because it was associated with slow clearance and high exposure after high-dose MTX
in leukemia patients (4), but the hypothesized association with a
good response was not observed in JIA patients. Interestingly, the
SLCO1B1 gene was not identified as a region of interest in the only
published genome-wide association study of MTX response in JIA
patients (14), but this study did not test for individual SLCO1B1
alleles.
There are some limitations to this study. Although the majority of patients were enrolled over the last 10 years, DNA samples and clinical data were combined from collections occurring

Figure 1. Response to methotrexate (MTX) is associated with
the number of SLCO1B1*14 alleles. The percent change in active
joint count versus number of SLCO1B1 alleles is plotted for
patients treated with MTX. Bars indicate median, whiskers indicate
interquartile range, and circles indicate each patient.
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over a 28-year period, leading to missing data for MTX route,
concomitant steroid usage, and/or the complete clinical data
required to calculate composite scores, such as ACR response
or juvenile arthritis disease activity score (JADAS). We utilized
the active joint count as the outcome measure because it was
available for all patients and remains a clinically meaningful outcome as well as a large driver for the ACR and JADAS composite
scores. An analysis of how the SLCO1B1*14 allele affects MTX
response as assessed by ACR or JADAS composite scores in a
validation cohort is needed. Further investigation of pharmacodynamic measurements, such as red blood cell MTX polyglutamate
concentrations in relation to SLCO1B1*14 allele status, may lend
additional support the hypothesis of faster clearance. Other variables that have been previously associated with response to MTX
that were not evaluated in this study, such as baseline folate polyglutamate profile (15), and gene expression (7) or protein levels
(16, 17), could account for some of the unexplained variability in
response. Nonetheless, the SLCO1B1*14 allele showed a significant association with response to MTX. Thus, the SLCO1B1
gene may be informative for precision dosing of MTX in JIA
patients. Patients carrying this allele may require a higher dose
than noncarriers to achieve a similar response to MTX, which
could be tested in future clinical trials of allele-guided dosing of
MTX.
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